Indications
Genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.
Composition
- Active substance
- elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide
- International name (INN)
- elvitegravir;cobicistat;emtricitabine;tenofovir alafenamide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Genvoya
- Active substance
- elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide
- ATC code
- J05AR